Literature DB >> 2656825

Importance of epidemiology and biostatistics in deciding clinical strategies for using diagnostic tests: a simplified approach using examples from coronary artery disease.

R E Patterson1, S F Horowitz.   

Abstract

The explosion of costly new medical diagnostic technologies demands a common sense approach to help physicians decide appropriate indications and strategies for use of these tests. This simple, nonmathematical review focuses on the assessment of coronary artery disease, but the approach can be generalized to other medical problems. This clinical approach to diagnostic testing strategies is based on seven sequential questions: 1. What is the clinical probability that this patient has a specific disease characteristic based on clinical data? 2. What is the overall objective for management of this patient based on the overall status of the patient? 3. Most importantly, what specific questions need to be answered about the patient's condition before the physician can recommend the most appropriate management (e.g., whether the patient has coronary disease, whether an anatomic lesion is functionally significant, whether a myocardial region is reversibly ischemic or irreversibly infarcted, whether a particular therapy has had good or bad effects or what is the patient's prognosis)? The key point is for the physician to formulate a specific clinical question about the patient before the test. 4. The physician must then ask how well does the test answer the particular clinical question about the patient. Here the physician needs to understand the sensitivity and specificity of the test, especially because they are influenced by various clinical biases. 5. Next, the physician must ask how to interpret the reliability of a positive or negative test result in the individual patient. This requires understanding predictive value and predictive error of a given result and how they are influenced by the clinical data as described by Bayes' theorem. 6. Next, the physician must ask what further tests or therapies will be recommended for the patient. The physician can estimate in advance how different test results would alter management plans and he can then allow this estimate to help determine indications for the test. There is some controversy concerning whether to use Bayes' theorem or multivariate analysis to estimate the final probability of a disease characteristic. 7. Finally, in this era of quality assurance, professional review and cost containment, it behooves each physician to ask whether the data provided by the particular tests were worth the cost, inconvenience and risk for that particular patient.

Entities:  

Mesh:

Year:  1989        PMID: 2656825     DOI: 10.1016/0735-1097(89)90361-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  Risk stratification after percutaneous transluminal coronary angioplasty.

Authors:  J R Burton; M Haraphongse; L Hsu; C T Kappagoda; R E Rossall; B Schlaut; M P Senaratne
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Viability assessment with MRI is superior to FDG-PET for viability: Con.

Authors:  Randolph E Patterson; Steven R Sigman; Robert E O'Donnell; Robert L Eisner
Journal:  J Nucl Cardiol       Date:  2010-04       Impact factor: 5.952

3.  Diagnostic value and incremental contribution of bicycle exercise, first-pass radionuclide angiography, and 99mTc-labeled sestamibi single-photon emission computed tomography in the identification of coronary artery disease in patients without infarction.

Authors:  A S Hambÿe; A Vervaet; S Lieber; R Ranquin
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

4.  Incremental diagnostic value of dipyridamole echocardiography and exercise thallium 201 scintigraphy in the assessment of presence and extent of coronary artery disease.

Authors:  V Di Bello; E Gori; C R Bellina; O Parodi; N Molea; G Santoro; G Mariani; U Conti; E Magagnini; P Marzullo
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

Review 5.  Clinical assessment following coronary revascularization.

Authors:  K J Beatt; F Fath-Ordoubadi; T Huehns
Journal:  Int J Card Imaging       Date:  1993

Review 6.  Cost-effectiveness analysis in diagnosis of cardiac disease: overview of its rationale and method.

Authors:  R E Patterson
Journal:  J Nucl Cardiol       Date:  1996 Jul-Aug       Impact factor: 5.952

7.  Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.

Authors:  Maja Guberina; Kaid Darwiche; Hubertus Hautzel; Till Ploenes; Christoph Pöttgen; Nika Guberina; Ken Herrmann; Lale Umutlu; Axel Wetter; Dirk Theegarten; Clemens Aigner; Wilfried Ernst Erich Eberhardt; Martin Schuler; Rüdiger Karpf-Wissel; Martin Stuschke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-05       Impact factor: 9.236

8.  Treadmill exercise stress echocardiography in patients with no history of coronary artery disease: a single-center experience in korean population.

Authors:  Jeong Yoon Jang; Il Suk Sohn; Jong Nim Kim; Jeong Hwan Park; Chang Bum Park; Eun Sun Jin; Jin Man Cho; Chong Jin Kim; Jong Hoa Bae
Journal:  Korean Circ J       Date:  2011-09-29       Impact factor: 3.243

9.  The Blood Pressure "Uncertainty Range" - a pragmatic approach to overcome current diagnostic uncertainties (II).

Authors:  Cornel Pater
Journal:  Curr Control Trials Cardiovasc Med       Date:  2005-04-06

10.  The methodological quality of three foundational law enforcement Drug Influence Evaluation validation studies.

Authors:  Greg Kane
Journal:  J Negat Results Biomed       Date:  2013-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.